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Abstract
Coxsackie B Virus (CBV) infection has been linked to the aetiology of type 1 diabetes (T1D)
and vaccination has been proposed as prophylaxis for disease prevention. Serum neutralis-
ing antibodies and the presence of viral protein and RNA in tissues have been common
tools to examine this potential disease relationship, whilst the role of anti-CBV cytotoxic T
cell responses and their targets have not been studied. To address this knowledge gap, we
augmented conventional HLA-binding predictive algorithm-based epitope discovery by
cross-referencing epitopes with sites of positive natural selection within the CBV3 viral
genome, identified using mixed effects models of evolution. Eight epitopes for the common
MHC class I allele HLA-A*0201 occur at sites that appear to be positively selected. Further-
more, such epitopes span the viral genome, indicating that effective anti-viral responses
may not be restricted to the capsid region. To assess the spectrum of IFNy responses in
non-diabetic subjects and recently diagnosed type 1 diabetes (T1D) patients, we stimulated
PBMC ex vivo with pools of synthetic peptides based on component-restricted sequences
identified in silico. We found responders were more likely to recognize multiple rather than a
single CBV peptide pool, indicating that the natural course of infection results in multiple tar-
gets for effector memory responses, rather than immunodominant epitopes or viral compo-
nents. The finding that anti-CBV CD8 T cell immunity is broadly targeted has implications for
vaccination strategies and studies on the pathogenesis of CBV-linked diseases.
Introduction
Coxsackie B viruses (CBVs) are a member of the diverse family of the picornaviridae. These
viruses demonstrate tropism for human cells, entering by ligation of the coxsackievirus and
adenovirus receptor. Whilst many human cases remain subclinical, CBVs can cause
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myocarditis and pancreatitis in neonates, the immunocompromised and the elderly. More
recently, there is the suggestion that this family of viruses may play a role in the initiation or
exacerbation of the pathogenesis of T1D, with some studies suggesting a particular association
with CBV1 [1] and others CBV4 [2]. A nationwide cohort study in Taiwan indicated an
increased risk of T1D in individuals presenting with enteroviral infection [3]. Furthermore,
CBV proteins and RNA have been found in pancreatic sections from T1D patients studied
post mortem [4]. Coxsackievirus RNA has also been detected in peripheral blood mononuclear
cells (PBMCs) at onset of disease in children [5]. A recent meta-review of available data con-
cluded that an overall increased risk of type 1 diabetes in association with coxsackievirus infec-
tion is indicated [6]. Preclinical mouse models of T1D support an association, as vaccination
can ameliorate acceleration of disease onset caused by CBV1 viral infection in this setting [7].
Taken together, such findings have been proposed as support for vaccination against CBV as a
prophylactic prevention to reduce or delay the onset of T1D.
The biology behind any potential causal association remains unclear, although there has
been the suggestion of potential molecular mimicry between the diabetes-related autoantigen
glutamic acid decarboxylase-65 and the CBV 2C protease [8]. CBV3 has been demonstrated to
enhance autophagy [9], on which in vivo pathogenesis of infection in pancreatic acinar cells is
dependent [10], and could therefore increase presentation of key disease-relevant autoanti-
gens. Murine studies have suggested that CBV4 infection of pancreatic beta cells enhances
phagocytosis by antigen presenting cells such as macrophages [11]. Combined with an inflam-
matory milieu associated with innate antiviral responses, this increase in autoantigen presenta-
tion may result in bystander activation or priming of autoreactive T cells to break tolerance
and initiate or exacerbate disease. Cytotoxic T cell responses could act as major players in host
cell death and pathogenesis, as has been shown to be the case for CBV viral myocarditis
[12,13]. For these reasons, identification of molecular targets for CBV-specific CD8 responses
would assist in assessing their role in pancreatic pathology, as well as being important for eval-
uating future vaccination approaches.
A previous approach to this question has been to predict CBV epitopes via a predictive algo-
rithm coupled with prolonged in vitro co-culture of PBMCs with putative target peptides to
elicit and measure T cell responses [14]. This approach has reduced specificity due to pro-
longed culture, and does not enable analysis of epitope regions that could be important for
viral clearance. In the present study, we aimed to augment and expand epitope prediction and
authentication for CBVs, by combining conventional MHC-binding algorithms with phyloge-
netic approaches to identify regions of the CBV genome evolving under positive selection to
identify epitopes from immunogenic regions. Given the high degree of genetic similarity
between enteroviruses, and the fact that T cell receptors can demonstrate high levels of cross-
reactivity [15], we also utilised high density pre-culture to increase sensitivity [16] in short-
term screening assays on human ex vivo blood samples to characterise potential CBV epitopes
associated with memory to CBV infection.
Materials and methods
In silico identification of putative CBV epitopes
Coxsackievirus sequences were submitted to HLA-Restrictor [17] for identification of peptides
with the potential to bind HLA-A0201. To generate consensus sequences for analysis, all pro-
tein sequences greater than 1800 amino acids that returned for the search terms “coxsackie-
virus B”; “CBV” and “CVB” from Genbank were aligned by ClustalW pairwise alignment,
edited and trimmed in MEGA6 [18]. Consensus sequence identity for each codon was identi-
fied using the Python package Bio.Align [19], taking 0.7 as a threshold for consensus identity
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at each amino acid site. Consensus sequences were generated for each serotype, as well as all
coxsackie B viruses irrespective of serotype. To remove the effect of overrepresented CBV sero-
types a consensus sequence of all serotype consensus sequences was generated as a “pan-CBV
consensus”. The proportion of sequences containing each putative CBV HLA-A0201 epitopes
was assessed manually in MEGA6.
Identification of sites of positive selection was performed using 38 full nucleotide sequences
of CBV3 available in GenBank. Sequences were aligned and trimmed in MEGA6 into frame
and starting from the codon sequence beginning “MGAQVST. . .” Aligned nucleotide
sequences were submitted to DataMonkey and checked for evidence of recombination by
GARD. Sites evolving under positive selection were identified using MEME analysis, taking p-
values<0.05 as significant [20].
Linear models were run in R (https://www.r-project.org/) and epitope radial plots gener-
ated in Strawberry Perl using the Circos package [21].
Identification of IFNy responses by ELISpot
This study was approved by the Bromley Research Ethics Committee (reference 08/H0805).
Venous blood was obtained from HLA-A02:01 positive non-diabetic donors, or HLA-
A02:01 patients with recent-onset T1D with written consent, and PBMC isolated by density
centrifugation as previously described [22]. PBMCs were cryopreserved to minimise variation
during assay performance. Anti-CBV CD8 T cell responses were evaluated using a direct IFNγ
ELISpot assay, in which PBMCs were thawed and rested for two days at high density (1.5 x107/
ml) in X-VIVO media + 5% human AB serum (Sigma). Cultured PBMCs were then recounted
and plated at 3.3x106/ml and 1x106 cells stimulated with a pool of 4 peptides at 5μg/ml each
final concentration (total final peptide concentration 20μg/ml) alongside diluent alone and
viral peptide mix CEF (Mabtech) control conditions for three hours. Samples were transferred
in triplicate to pre-coated and blocked IFNγ ELISpot plates (U-Cytech) and incubated for 24
hours to capture cytokine released. Cytokine release was identified as per the manufacturer’s
instructions and plates counted using the Bio-sys Bioreader, as described previously [23–29].
Results are expressed as stimulation indices (SI) normalised to diluent-only control per 3.3 x
105 cells (SIs of 2 and above were considered a positive response).
Serum plaque neutralisation assay
Serum samples, diluted to 1 in 4 and 1 in 16 with serum free DMEM, were incubated with 200
pfu virus for 90 minutes before inoculation of a GMK monolayer in 96 well plates. After 1
hour with intermittent agitation, the inoculum was removed and an agarose-media plug lay-
ered onto the cells to prevent viral dissemination through the media. Assays were left for 48
hours for plaques to develop, before harsh fixation with Carnoy’s fix, washing, plug removal
and staining with crystal violet. Plates were imaged using a Bio-sys Bioreader and restriction of
virus-plaque formation quantified against virus-only inoculation controls. Virus strains used
were: Coxsackievirus B1 (ATCC1 VR-28™)–Conn strain; Coxsackievirus B 2 (ATCC1 VR-
29™)–Ohio strain; Coxsackievirus B3 (ATCC1 VR-30™)–Nancy strain; Coxsackievirus B4
(ATCC1 VR-184™)–J.V.B strain; Coxsackievirus B 5 (ATCC1 VR-185™)–Kentucky strain and
Coxsackievirus B 6 (ATCC1 VR-155™)–Schmitt strain.
Statistical analysis
Statistical analyses were performed in Prism 5, unless otherwise indicated. Tests used include
Fisher’s exact and Student’s t test as indicated.
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Results
Phylogenetic analysis of available whole-genome coxsackievirus B
sequences
We sought to identify potential MHC-I restricted epitope targets from coxsackievirus sequence
data available on Genbank in silico by generating consensus sequences that could be interro-
gated for HLA-A0201-binding epitopes. A search for sequences greater than 1800 amino
acids in length on Genbank returned 9 sequences for CBV1, 4 for CBV2, 27 for CBV3, 23 for
CBV4, 11 for CBV5 and 5 for CBV6 for alignment (S1 Table). This alignment was used to
build a maximum likelihood phylogenetic tree and confirmed that sequences labelled as
belonging to a particular serotype clustered together (Fig 1).
We highlight the degree of consensus for each amino acid site in each polyprotein compo-
nent within and across serotype sequences in Fig 2A. This figure shows the most conserved
region between the serotypes by this measure to be the c3 protease region, with no site reach-
ing below the threshold of 0.7 for the consensus level. Conversely, the most variable regions
Fig 1. Phylogenetic analysis of available CBV sequences. Polyprotein sequences returned from Genbank for the
terms “coxsackievirus B”; “coxsackie B virus”; “CBV”; “CVB”, listed in Table 1, were aligned using ClustalW pairwise
alignment in Mega6. Genetic similarity between sequences and serotype clades in this alignment was assessed by
generation of a maximum-likelihood phylogenetic tree. Sequences for CBV1 (10- highlighted in blue), CBV2 (7- light
blue), CBV3 (29- red), CBV4 (25-purple), CBV5 (15-orange) and CBV6 (6- green) all clustered together with
sequences for the same serotype, as would be expected from their labelling on Genbank.
https://doi.org/10.1371/journal.pone.0199323.g001
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between the serotypes were the capsid proteins. VP1 was most variable, with only 67.91% of
amino acids conforming to the pan-serotype consensus sequence in this region. Variation
within each serotype was greatest in the 2A component of the polyprotein with approximately
92% conforming to the consensus sequence (Fig 2B).
Identification of serotype specific MHC-I-restricted epitopes in silico
We submitted the consensus sequence for all coxsackie B virus serotypes to analysis by HLA-
restrictor, for prediction of epitopes that could bind HLA-A0201. We calculated the preva-
lence of each epitope returned from this analysis within the sequences of the alignment. The
regions of 2A and 2B were significantly underrepresented in the epitopes found using HLA-
restrictor, despite successfully generating a consensus sequence for this region. We therefore
extracted coxsackievirus B sequences for this region from Genbank and generated a consensus
sequence at a lower threshold of 0.4 to submit to HLA-restrictor to return more potential epi-
topes. We also identified serotype specific epitopes by submitting consensus sequences for
each CBV serotype to HLA-restrictor from which exclusive epitopes were identified manually.
These serotype specific epitopes were restricted almost entirely to the capsid regions of the
Fig 2. Conformation of viral component amino acid sequences to Pan-CBV and serotype-specific consensus
sequences. To identify the protein components accounting for the greatest variance between sequences and serotypes
used in our analyses, a pan-CBV consensus sequence was generated using Python Bio.Align package (using a threshold
of 0.7) for all sequences for all serotypes, and the proportion of sequences conforming to this consensus sequence was
determined for each amino acid site (A). Consensus sequences were also generated for each serotype, and the
proportion of sequences within each specific serotype conforming to their consensus sequence was determined for
each amino acid site for each viral protein (B).
https://doi.org/10.1371/journal.pone.0199323.g002
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virus (Fig 3A, outer to inner track of histograms: CBV1, CBV2, CBV3, CBV4, CBV5, CBV6).
This analysis demonstrates that while the level of consensus between different serotypes is low
in the capsid, this region appears to be highly immunogenic across serotypes. At position 538
within the VP3 capsid region, we identified a different HLA-A0201 binding epitope within
each serotype (Table 1 and Fig 3B).
These epitopes indicate that VP3 remains immunogenic despite substantive change during
the differentiation of the serotypes, and could be used to detect serotype-specific MHC class I-
restricted immunity. Such tools would be particularly useful in investigating the potential role
of viral infection in T1D, as infection with CBV1 [1] or CBV4 [30] has been purported as a
mechanism driving onset of disease. We therefore utilised synthetic peptides designed from
VP3 sequences to stimulate PBMC from healthy controls and recently diagnosed patients with
T1D in short term-ELISpot assays to detect serotype-specific MHC-I restricted IFNγ responses
(Fig 3C). We detected low amplitude responses to all peptides, except for the CBV5-derived
sequence TQSDCKILCFV. Despite the low predicted affinity for the CBV4-derived epitope
AQKSCYIMCFV, we detected two responders from the 24 individuals tested. The CBV1
sequence VQSSCDVLCFV had the greatest number of responders, with two controls and one
T1D returning a positive IFNγ response. Of the five ELISpot responders, all had either strong
or weak serum neutralising antibody responses to the serotype they demonstrated a positive
ELISpot to (S2 Table). They, like the ELISpot non-responders also demonstrated neutralisation
against most other serotypes. These ELISpot responses suggest that the epitopes we identified
Fig 3. IFNy responses can be detected against epitopes at VP3 positions 538–548 in serotypes CBV1, 2, 3, 4 and 6.
(A) Consensus sequences for CBV serotypes 1–6 were submitted to HLA-restrictor and returned putative
HLA-A0201 binding epitopes. The prevalence of these epitopes was assessed manually and serotype-unique
sequences were presented in a radial plot. The radial tracks represent CBV serotypes 1–6, the outermost track of red
histograms represents CBV1, blue CBV2, purple CBV3, green CBV4, rust CBV5 and aqua CBV6. The height of the
histograms indicates the percentage of sequences within the indicated serotype that contain the epitope of interest at
that site. The outer green tiles highlight the viral component. All serotypes of CBV had a putative HLA-A0201 epitope
at positions 538–548 within the VP3 region, which is highlighted in the alignment of consensus sequences presented in
(B). (C) Cryopreserved PBMCs from non-diabetic controls (grey circles) and recently diagnosed T1D patients (blue
squares) were thawed and pre-cultured at high density for 48 hours before stimulation with synthetic peptides (each at
a final concentration of 5ug/ml) for the 538–548 epitopes in an IFNγ ELISpot. The results are normalised to DMSO
controls and expressed as mean stimulation index (SI) per 3.3 x 105 cells. We used a short-term ELISPot stimulation of
24 hours to ensure we did not prime naïve precursors and to minimise potential false positives from TCR promiscuity.
https://doi.org/10.1371/journal.pone.0199323.g003
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in silico at VP3 538–548 can be used to screen for CBV serotype-biased MHC-I restricted
immune responses.
Mixed effects model of evolution identifies sites of positive selection within
putative anti-CBV HLA-A02:01 binding epitopes
To examine the role of positive selection, potentially from the immune system, in driving vari-
ation in coxsackie B viruses we used Datamonkey’s web-based application [20] to identify
codons that had significantly more nonsynonymous mutations within the population using a
mixed effects model of evolution (MEME). There is particular interest in generating a CBV1
capsid based vaccine for clinical use [7], so we performed a MEME analysis using sequences
returned from Genbank for the VP1 region of CBV1 (S3 Table) in order to identify sites that
could be generating key anti-viral responses. We identified eight sites of positive selection
within VP1 (S4 Table), including three consecutive sites at codons 676, 677 and 678 (Fig 4A).
These consecutive sites coincided with a putative HLA-A0201 binding epitope present in 40%
CBV1 sequences (KLELFTYL 675–682) with a predicted binding affinity of 104nM. We found
that HLA-restrictor predicted an HLA-A0201 binding epitope at these positions for all sero-
types of CBV (Fig 4B). The epitopes were 8-mers that differed in amino acid identity at posi-
tions 2, 4 and 8. We catalogued all available sequences for these sites in VP3 across all six
serotypes and found that amino acid identities at positions 2 and 4 had a major impact on
their predicted binding affinity for HLA-A02:01 (Fig 4C). We also compared the prevalence
of each sequence with its predicted binding affinity for HLA-A0201 (Fig 4D). We found
that apart from the sequence for CBV5, which was present in 95% of sequences analysed and
had a predicted binding affinity of 254nM, sequences with no or a low affinity for binding
HLA-A0201 were present at lower frequencies. Similarly, the few epitopes present with a
strong predicted binding affinity (<55nM) were also present at low frequencies. These obser-
vations suggest that despite immune pressure in this region, non-synonymous substitutions
that alter the biophysical properties of this region too extremely are disadvantageous to the
virus, as are substitutions that increase affinity of binding to a common HLA allele such as
HLA-A0201, making this region of great interest for vaccination strategies against CBV1 and
other serotypes of CBV.
To date, most approaches in assessing the role of coxsackievirus infection in accelerating
onset of T1D have centred on hypotheses of a diabetogenic serotype, or even strain [31] of
CBV. We sought to test an alternate hypothesis that the targets of anti-CBV immune responses
differ between non-diabetic control subjects and patients with T1D. To do so we generated
pools of synthetic peptides derived from each viral protein of CBV, to use as stimuli in ex vivo
PBMC assays. To prioritise inclusion of epitopes from putatively immunogenic regions, we
performed a MEME analysis for full length sequences of CBV3, the most highly-represented
serotype on GenBank, to identify sites under positive selection. We hypothesised that most
Table 1. Synthetic peptides used to detect serotype-specific anti-CBV responses in ELISpot assays.
Serotype Sequence Predicted Affinity (nM)
CBV1 VQSSCDVLCFV 39
CBV2 ALSTCYIMCMV 11
CBV3 AQSSCYIMCFV 11
CBV4 AQKSCYIMCFV 361
CBV5 TQSDCKILCFV 70
CBV6 AQSNCSILCFV 27
https://doi.org/10.1371/journal.pone.0199323.t001
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sites under positive selection would be within the capsid. Interestingly, in addition to 16 sites
within the capsid, we identified a further 20 sites in other viral components that appeared to be
evolving under positive selection (S5 Table and Fig 5A). Five of the capsid and four of the non-
capsid sites of positive selection lay within a predicted HLA-A0201 epitope. To assess the
presence of CD8 memory responses in human peripheral blood against coxsackievirus epi-
topes identified by our in silico analyses, we selected pools of four peptides for each viral com-
ponent to use in ex vivo stimulation assays. Epitopes derived from regions that contained a site
of positive selection in our previous MEME analysis were prioritised and additional peptides
with the highest predicted HLA-A2-binding affinity (no weaker than 150nM) to make up
pools of four peptides per viral component. In the case of VP4, there were only two potential
epitopes returned using HLA-restrictor. We therefore submitted sequences to SYFPEITHI[32]
which returned two additional peptides to bring the VP4 pool up to four. These were taken
forward for functional studies (Table 2 and Fig 5B).
Ex vivo IFNy responses can be detected against capsid and non-capsid
As several studies have suggested CBV infection may precede T1D diagnosis, we hypothesised
that we would be more likely to detect CD8 memory responses against CBV peptide pools in
recently diagnosed patients with T1D than in non-diabetic controls. To test for pre-existing
Fig 4. MEME analysis of CBV1 VP1 sequences reveal putative immunogenic regions across serotypes of CBV. (A)
Trimmed and edited CBV1 VP1 sequences from Table 4 were aligned by Bio.Align in Python and submitted to
Datamonkey to identify sites of positive selection by mixed effects model of evolution. The p-value for the significance
of which the amino acid site is evolving under positive selection within the model is represented. (B) Epitopes present
at VP1 684–692 are highlighted within an alignment of serotype consensus sequences. (C) The predicted affinity for all
potential sequences at VP1 684–692 are plotted against the amino acid identity for positions 2 and 4 in the 8-mer. (D)
Prevalence of each sequence present at sites 682–694 for all serotypes was determined and plotted against their
predicted binding affinity for HLA-A0201, determined by HLA-restrictor.
https://doi.org/10.1371/journal.pone.0199323.g004
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Fig 5. Circos plot indicating the prevalence of viral protein component epitopes across CBV serotypes. (A)
Trimmed and edited CBV3 sequences from Table 1 were aligned by Bio.Align in Python and submitted to
Datamonkey to identify sites of positive selection by mixed effects model of evolution. The p-value for the significance
of which the amino acid site is evolving under positive selection is represented. (B) The percentage of sequences for
each serotype containing each epitope was calculated manually and presented as histograms in a Circos plot. The radial
tracks represent CBV serotypes 1–6, the outermost track of red histograms represents CBV1, blue CBV2, purple CBV3,
green CBV4, rust CBV5 and aqua CBV6. The height of the histograms indicates the percentage of sequences within the
indicated serotype that contain the epitope of interest at that site. The outer green tiles highlight the viral component.
The outermost purple highlights indicate the presence of a site of positive selection within the CBV3 genome.
https://doi.org/10.1371/journal.pone.0199323.g005
Identification of CBV MHC-I epitopes in silico and ex vivo
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cellular immunity to CBVs, cryopreserved PBMCs were thawed and pre-cultured at high den-
sity for 48 hours before stimulation with CBV peptide pools designed in the previous section
in a short-term IFNγ ELISpot assay. We observed responses to the capsid-derived peptide
pools, though there were also multiple responders to the 2B component pool (Fig 6A and
Table 2. Synthetic peptides used to detect anti-CBV T cell responses in ELISpot assays.
ID Region Start Stop Length PSS PSS AA Sequence PredictedAffinity (nM)
220 VP4 10 19 18 N TGAHETGLNA
221 VP4 22 31 30 I NSIIHYTNIN
86 VP4 60 68 9 - - VMIKSMPAL 36
71 VP4 60 68 9 - - IMIKSMPAL 29
25 VP2 169 179 11 117 I YLGRTGYTIHV 10
14 VP2 271 279 9 - - LVMPYINSV 7
12 VP2 291 298 8 - - TLMIIPFV 6
42 VP2 294 301 8 - - MIIPFVPL 17
3 VP3 450 458 9 - - FMFCGSAMA 3
5 VP3 462 471 10 - - FLLAYSPPGA 4
22 VP3 480 490 11 - - AMLGTHVIWDV 9
28 VP3 545 554 10 - - FVSACNDFSV 11
222 VP1 582 590 583/590 MV AMVRVADTV 60
66 VP1 639 646 8 - - FLCRSACV 26
127 VP1 713 721 9 721 V ILTHQIMYV 8
121 VP1 718 727 10 - - IMYVPPGGPV 88
151 2A 910 920 11 - - IIARCQCTTGV 96
134 2A 932 942 11 - - VVFEGPGLVEV 17
135 2A 952 960 9 - - YQTHVLLAV 17
223 2A 970 978 975 E GILRCEHGV 453
119 2B 997 1007 11 - - WLEDDAMEQGV 80
46 2B 1053 1062 10 - - ALVKIISALV 19
61 2B 1056 1064 9 - - KIISALVIV 24
120 2B 1093 1101 9 - - SQYYGIPMA 83
100 2c 1222 1230 9 - - LLLHGSPGA 46
24 2c 1242 1251 10 - - SLAEKLNSSV 10
11 2c 1285 1294 10 - - SLFCQMVSSV 6
33 2c 1308 1316 9 - - ILFTSPFVL 13
36 3a 1441 1448 8 - - ALFQGPPI 14
90 3A 1447 1455 9 - - AIADLLKSV 39
74 3A 1470 1479 10 - - WLVPEINSTL 31
47 3A 1490 1498 9 - - CLQAITTFV 20
67 c3 1556 1565 1564 T AMMKRNSSTV 27
15 c3 1563 1573 11 - - TMLGIYDRWAV 7
9 c3 1626 1634 9 - - FLAKEEVEV 6
45 c3 1682 1691 10 - - MLMYNFPTRA 17
224 3D 1923 1930 1954 D AFHQNPGIVT 42
225 3D 1953 1960 2184 T LDGHLIAFD 16
43 3D 1960 1967 8 - - SLSPVWFA 17
89 3D 1995 2005 11 - - YIDYLCNSHHL 38
Predicted affinity from HLA-restrictor
https://doi.org/10.1371/journal.pone.0199323.t002
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S6 Table). We detected positive IFNγ responses to CBV peptide pools in 4/18 non-diabetic
controls and 4/19 recently diagnosed patients (no significant difference in distribution by Fish-
er’s exact test (Fig 6B)). Responders generally exhibited IFNγ responses to more than one CBV
peptide pool, and there was no significant difference in the number of pools that controls and
patients responded against (Fig 6C). In addition, there was no significant difference in the con-
solidated stimulation indices for CBV responses between the two groups (Fig 6D). We found
that the presence of serum neutralising antibodies, as determined by plaque neutralisation
assay, was largely equivalent in cases and controls of serum samples tested from this cohort
(S1A Fig). There were no significant differences in time since diagnosis for patient responders
and non-responders to the CBV pools (S1B Fig), nor were there any differences between the
two groups of CBV-responders in magnitude of IFNy responses to a positive control viral pep-
tide mix (S1C Fig) and age (S1D Fig). Overall, these data do not indicate an association of anti-
CBV immunity with T1D. However, this ex vivo data does suggest that CBV infection can gen-
erate IFNγ responses against not only capsid proteins, but also non-structural proteins such as
Fig 6. IFNγ responses to CBV viral component peptide pools in non-diabetic controls and recently-diagnosed
T1D patients. PBMC from non-diabetic and recently diagnosed -T1D patients were pre-cultured at high density for
48 hours before stimulation with pools of CBV and control peptides for 18 hours in an IFNγ ELISpot assay. Spots are
reported as mean stimulation index normalised to DMSO control for 3.3 x 105cells. (A) Stimulation indices for cohort
responses to viral component CBV pools and serotype specific CBV pools (B) are presented. (C) The number of
individuals demonstrating positive IFNγ ELISpot responses to any CBV derived peptide pool for ND-T1Ds and non-
diabetic controls. (D) The number of positive hits for CBV peptide pools in responders is plotted for control and
recently-diagnosed T1D cases.
https://doi.org/10.1371/journal.pone.0199323.g006
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proteases 2A and 2B, and polymerase 3D. These data support our suggestion that the positive
selective pressure we observed outside of the capsid region of CBV may be immune mediated
and specifically related to the potential for viral sequences to bind such a common MHC class
I allele as HLA-A0201.
Discussion
Observational studies linking infection with coxsackievirus (and other enteroviruses) to T1D
[3,6,33–36] have given rise to a number of experimental studies in preclinical models of the
disease that support a role for infection in exacerbating pathological processes, an effect which
vaccination against the virus can negate [7]. These observations have generated interest in the
possibility of prophylactic vaccination against potentially diabetogenic CBV strains to reduce
or delay the development of T1D [37]. Characterisation of CD8 epitope targets associated with
viral infection would provide useful tools to monitor CBV responses in cohort studies and
track the efficacy of vaccination approaches. The present study shows that many sites through-
out the CBV3 genome appear to be evolving under positive selection by the immune system.
This finding suggests a key role for immune responses outside of neutralising antibodies,
which are typically considered the most important component of the anti-CBV response due
to the predisposition of agammaglobulinemic patients to enteroviral encephalitis [38,39]. As
neutralising antibodies target capsid, immune selective pressure on sites within non-structural
proteins most likely derive from antigens generated during intracellular phases of the viral life
cycle, or from internalisation of pathogen components by professional antigen-presenting
cells. These antigens could prime either helper or cytotoxic T cell responses. These findings
imply that successful generation of these cellular responses must be integral to the clearance of
the virus for such selective pressure on non-structural components to be apparent. This new
insight within the human system provides a series of potential targets through which to moni-
tor immune responses to infection and vaccination, as well as holding implications for vaccine
design.
By utilising high density pre-culture [16] before a short-term culture IFNy ELISpot assay
to test epitopes on human ex vivo PBMCs, we were able to detect more specific memory
responses than would be possible in a long term culture assay, in which priming and cross-
reactivity have the potential to skew results. In this small-scale study, there was no single
immunodominant epitope identified and we detected only low amplitude responses in a
minority of individuals tested. A technical issue to account for this could be the use of pooled
peptides, as in our laboratory we have observed lower SIs in response to a pool than when the
individual peptides have been tested in the same donor. Aside from this, there are several bio-
logical interpretations that could be made for this result. First, is that successful clearance of
enteroviruses is dependent on broad low level T cell responses, consistent with our in silico
observations that sites across capsid and non-capsid regions evolve under immune pressure.
Second, epitopes that contain amino acids from sites evolving under positive selection may dif-
fer across individuals, so we may be identifying a minority of responses that target this region
of the genome. Third, the findings are consistent with our current understanding of the biol-
ogy of CBVs. Viruses associated with chronic and recurring infections such as human cyto-
megalovirus [40], human Epstein-Barr virus [41], and influenza viridae [42], tend to focus
cellular immune responses onto immunodominant regions, which are reprimed through
repeated antigen exposure through-out life. What we have observed is a broad and low level
specificity of CVB responses suggestive of resolved infection and long term protection, which
is known to be predominantly maintained throughout life by neutralizing antibody. As a next
step to studying the most plausible of these explanations that are also experimentally testable,
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we would propose a study in children, in whom CVB infection is likely to be more immediate
and therefore characterised by a higher amplitude of cellular immune memory responses.
However, given the blood volume requirements, such a study would need to be focused onto a
discrete panel of epitopes informed by studies such as this one. These contrasting findings
between types of virus immunity also imply that CBV infection does not have a chronic phase,
or at least not one during which there is exposure to CD8 responses. Finally, CBV3 in animal
models has been shown to actively suppress formation of CD8 memory responses [43], poten-
tially by effecting dendritic cell stimulatory capacity [44]. In this light, our data may support
the view that this also occurs in the human system for CBV3 and other serotypes, as all individ-
uals tested had neutralising antibodies against at least two serotypes of CBV, the majority
restricting plaque formation by four or more serotypes (S2 Table), but only 20% demonstrated
positive ELISpots for CBV-derived MHC-I restricted epitopes.
Ex vivo analyses showed a diverse spread of epitope targets across individuals when positive
ELISpot responses against CBV peptide pools were detected. Responders generally demon-
strated low amplitude IFNy ELISpots to more than one pool of CBV-derived peptides, indicat-
ing the generation of multiple-specificities of CD8 memory over the course of an infection. In
relation to our secondary objective, to examine potential differences in CD8 responses to CBV
in patients with T1D compared with non-diabetic controls, we did not observe any differences
in the prevalence or breadth of responses. These results should be interpreted cautiously at this
stage since our subject numbers were small and due to the large volume of blood required for
the ex vivo ELISpot screens we studied adult rather than childhood subjects (in whom entero-
virus infections are more frequent). We have also studied subjects at a late stage of a disease
that has a long prodrome, with the risk that we have missed important early events. Our study
provides a systematic analysis of CBV epitopes that should be of use in designing more exten-
sive studies at earlier disease stages, to address these issues.
Supporting information
S1 Fig. Serum neutralising antibody responses and other key confounding parameters
were equivalent in the two arms of the cohort study. (A) For individuals where samples were
available, serum neutralisation of plaque formation by coxsackievirus serotypes 1–6 was
assayed as an indicator of serum neutralising antibodies, and so previous virus exposure.
Weak neutralisation was defined as a greater than 50% reduction in the number of plaques
formed using a 1 in 4 dilution of serum, whilst strong neutralisation was defined by a greater
than 50% reduction in the number of plaques using 1 in 16 dilution of serum. The percentage
of samples with neutralising capacity for each serotype is presented for recently diagnosed
T1Ds (n = 10 for CBV1 and CBV2, n = 11 for CBV3- 6) and non-diabetic controls (n = 9 for
CBV1, n = 7 for CBV2 and n = 10 for CBV3-6). Months since diagnosis (B); SI per 3.3 x 105
PBMC for positive control CEF (C) and age (D) are plotted for recently-diagnosed T1Ds
against non-diabetic controls and CBV-responders and non-responders. (E) Mean SIs for
individuals responding to any CBV peptide pool are plotted against the number of positive
hits for that individual. Dark grey points indicate ND-T1Ds and light grey points indicate
non-diabetic controls.
(TIF)
S1 Table. Sequences used for serotype specific and pan-serotype epitope prediction.
Sequences returned from Genbank for the queries “CBV”, “CVB” “Coxsackievirus B” and
“Coxsackie B Virus” were collated for use in in silico epitope prediction approaches.
(DOCX)
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S2 Table. Serotype specific ELISpot responses and serum plaque formation neutralisation
assay results. Cryopreserved PBMCs were thawed and rested for two days at high density (1.5
x107/ml) in X-VIVO media + 5% human AB serum (Sigma). Cultured PBMCs were then
recounted and plated at 3.3x106/ml and 1x106 cells stimulated with indicated peptides at 5μg/
ml each final concentration, alongside diluent alone and viral peptide mix CEF (Mabtech) con-
trol conditions for three hours. Samples were transferred in triplicate to pre-coated and blocked
IFNγ ELISpot plates (U-Cytech) and incubated for 24 hours to capture cytokine released. Cyto-
kine release was identified as per the manufacturer’s instructions and plates counted using the
Bio-sys Bioreader. The mean IFNy SI per 3.3x105 cells of three replicate wells and total spots
per 106 are presented for ELISpot assays against serotype specific epitope at position 538–548.
Results from the neutralisation of CBV plaque formation by serum assays are also presented;
strong responses were taken as those sera reducing plaque formation by 50% with a 1 in 16
dilution of serum, and weak responses were taken as those sera that reduced plaque formation
by 50% with a 1 in 4 dilution of serum when compared to virus only controls.
(DOCX)
S3 Table. Sequences used for CBV1 VP1 MEME. Sequences returned from Genbank for the
queries “CBV1”, “CVB1”, “Coxsackievirus B1” and “Coxsackie B Virus 1” were collated for use
in in silico epitope prediction approaches.
(DOCX)
S4 Table. Sites of positive selection identified in CBV1 VP1 by MEME. The sites of positive
selection identified in CBV1 VP1 sequences available on Genbank are presented, along with
the predominant amino acid present at that site and any HLA-A02:01 binding epitopes con-
tained within the site.
(DOCX)
S5 Table. Sites of positive selection identified in CBV3 by MEME. Full length sequences
returned from Genbank for the queries “CBV3”, “CVB3”, “Coxsackievirus B3” and “Coxsackie
B Virus 3” and used to identify sites evolving under positive selective pressure using Datamon-
key’s mixed effects model of evolution packages. Sites that were identified as evolving under
positive selection are listed, along with HLA-A02:01 binding epitopes that incorporate that
site.
(DOCX)
S6 Table. Raw data for viral component pool ELISpot assays. Cryopreserved PBMCS were
thawed and precultured at high-density for 48 hours as preparation for ELISpot assay. PBMCs
were then recounted and plated at 3.3x106/ml and 1x106 cells stimulated with a pool of 4 pep-
tides at 5μg/ml each final concentration (total final peptide concentration 20μg/ml) alongside
diluent alone and viral peptide mix CEF (Mabtech) control conditions for three hours. Sam-
ples were transferred in triplicate to pre-coated and blocked IFNγ ELISpot plates (U-Cytech)
and incubated for 24 hours. Cytokine release was identified as per the manufacturer’s instruc-
tions and plates counted using the Bio-sys Bioreader. The mean IFNy SI per 3.3x105 cells of
three replicate wells and total spots per 106 are presented for ELISpot assays against viral com-
ponent specific peptide pools.
(DOCX)
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